SCHEMBL3303787

SCHEMBL3303787

CCc1ccc2c(c1)[C@H](NC(=O)c1ccc(F)cc1)[C@H](O)C(C)(C)O2

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ABCC9 O60706 4/20 0.59
KCNA5 P22460 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7475538 1.00 ABCC9 (0.59) ABCC9KCNA5
SCHEMBL7478774 1.00 ABCC9 (0.59) ABCC9KCNA5
SCHEMBL3304984 1.00 ABCC9 (0.59) ABCC9KCNA5
SCHEMBL7485366 1.00 ABCC9 (0.59) ABCC9KCNA5
SCHEMBL9375657 0.89 ABCC9 (0.57) ABCC9
SCHEMBL8341375 0.89 KCNA5 (0.60) ABCC9KCNA5
SCHEMBL8341370 0.89 KCNA5 (0.60) ABCC9KCNA5
SCHEMBL8341372 0.89 KCNA5 (0.60) ABCC9KCNA5
SCHEMBL7481173 0.89 ABCC9 (0.66) ABCC9
SCHEMBL7481178 0.89 ABCC9 (0.66) ABCC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC. (GB) 2010-04-22 US claimed
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC 2007-04-19 US claimed
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2003-12-25 US claimed
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2002-09-05 US claimed
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2001-09-13 US claimed
EP-0673374-B1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-03-01 EP claimed
EP-0673374-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1995-09-27 EP claimed
WO-1994013657-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-06-23 WO claimed
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC. (GB) 2010-04-22 US disclosed
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC 2007-04-19 US disclosed
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2003-12-25 US disclosed
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2002-09-05 US disclosed
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEECHAM P.L.C. 2001-09-13 US disclosed
EP-0673374-B1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-03-01 EP disclosed
US-5948811-A Pharmaceutical composition containing bicyclic type compounds SMITHKLINE BEEGHAM P.L.C. (GB) 1999-09-07 US disclosed
WO-1994013657-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1994-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236410-A1 Pharmaceutical composition containing bicyclic type compounds CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2B6 ABCC9 162/4885KCNA5 432/4885
US-20070088064-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH, CBR3 ABCC9 155/4885KCNA5 579/4885
US-20010021780-A1 Pharmaceutical composition containing bicyclic type compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CLIC1, NAF1 ABCC9 122/4885KCNA5 548/4885
US-20100099752-A1 PHARMACEUTICAL COMPOSITION CONTAINING BICYCLIC TYPE COMPOUNDS SNCA, GRIN2C, PYGB ABCC9 1314/4885KCNA5 748/4885
US-20020123630-A1 Pharmaceutical composition containing bicyclic type compounds CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CFH ABCC9 111/4885KCNA5 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.